1-20 of 31
Lisa Drew
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract ND06: First disclosure of AZD8421, a highly selective CDK2 inhibitor to address resistance to CDK4/6 inhibitors in breast and CCNE1-high cancers

Christopher R. Denz, Michael Grondine, Jun Fan, Jessie Hao-Ru Hsu, Anne Jackson, James Robinson, Grace Guo, Wen Li, Yanjun Wang, Maryann San Martin, Laura Prickett, Jeffrey Johannes, Avipsa Ghosh, Kun Song, Dhivya Sudhan, Christina Vasalou, Ryan Richards, Kevin Beaumont, Matthew Peters, Lisa Drew, Stephen Fawell, Frederick W. Goldberg
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): ND06.
https://doi.org/10.1158/1538-7445.AM2024-ND06
Published: 05 April 2024
View articletitled, Abstract ND06: First disclosure of AZD8421, a highly selective CDK2 inhibitor to address resistance to CDK4/6 inhibitors in breast and CCNE1-high cancers
Journal Articles

Abstract 5730: Targeting the cell cycle with AZD8421, a potent and highly selective CDK2 inhibitor

Christopher R. Denz, Michael Grondine, Jun Fan, Jessie Hao-Ru Hsu, Anne Jackson, James Robinson, Grace Guo, Wen Li, Yanjun Wang, Maryann San Martin, Laura Prickett, Jeffrey Johannes, Avipsa Ghosh, Dhivya Sudhan, Christina Vasalou, Ryan Richards, Kevin Beaumont, Matt Peters, Lisa Drew, Stephen Fawell, Frederick W. Goldberg
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 5730.
https://doi.org/10.1158/1538-7445.AM2024-5730
Published: 22 March 2024
View articletitled, Abstract 5730: Targeting the cell cycle with AZD8421, a potent and highly selective CDK2 inhibitor
Journal Articles

Abstract 7089: Proteomic evaluation of combination data in acute myeloid leukemia to inform mechanism of action and new targets

Lori Chan, Zuleyha Ozen, Anthony Iannetta, Eric Miele, Funda Kar, Andrew Jarnuczak, Geoff Nelson, Aleksandra Markovets, Justine Roderick-Richardson, Jelena Urosevic, Lisa Drew, Jerome Mettetal
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 7089.
https://doi.org/10.1158/1538-7445.AM2024-7089
Published: 22 March 2024
View articletitled, Abstract 7089: Proteomic evaluation of combination data in acute myeloid leukemia to inform mechanism of action and new targets
Journal Articles

Abstract 3904: Multiplexed flow cytometry based immunophenotyping paired with functional ex vivo (MFLEX) drug profiling informs potential efficacy of therapeutic agents in acute myeloid leukemia

Reecha Shah, Heba Wander, Michelle Hsueh, Muskan Floren, Wei Liu, Patricia Cheung, Courtney Andersen, Michael White, Nathan Kingston, Pablo Morentin Gutierrez, Lisa Drew, Giulia Fabbri, Elena Bibikova, Daniel Auclair
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3904.
https://doi.org/10.1158/1538-7445.AM2024-3904
Published: 22 March 2024
View articletitled, Abstract 3904: Multiplexed flow cytometry based immunophenotyping paired with functional ex vivo (MFLEX) drug profiling informs potential efficacy of therapeutic agents in acute myeloid leukemia
Journal Articles

Abstract 4605: AZD4573 in combination with CHOP increases combination benefit in preclinical peripheral T-cell lymphoma models

Danielle Sinead Potter, India Ott, Jamal Saeh, Richard Olsson, Stephen Fawell, Lisa Drew, Justine Roderick
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 4605.
https://doi.org/10.1158/1538-7445.AM2024-4605
Published: 22 March 2024
View articletitled, Abstract 4605: AZD4573 in combination with CHOP increases combination benefit in preclinical peripheral T-cell lymphoma models
Journal Articles

Abstract 5321: Large scale pan cancer drug combination screening to identify effective and actionable combinations and biomarker hypothesis

Azadeh Bashi, Elizabeth A. Coker, Krishna Bulusu, Marta Milo, Claire Crafter, James Lynch, David Jenkins, Howard Lightfoot, Brandon Willis, Courtney Andersen, Omid Tavana, Kevin Mongeon, Jacob Gordon, Paul Smith, Simon Barry, Ultan McDermott, Lisa Drew, Susan Critchlow, Mathew J. Garnett, Jerome Mettetal
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5321.
https://doi.org/10.1158/1538-7445.AM2023-5321
Published: 04 April 2023
View articletitled, Abstract 5321: Large scale pan cancer drug combination screening to identify effective and actionable combinations and biomarker hypothesis
Journal Articles

Abstract 3271: BRD4 inhibition enhances the acalabrutinib tumor response by modulating PAX5 and interferon signaling in ABC-DLBCL

Derek B. Oien, Samanta Sharma, Ye Xu, Maureen Hattersley, Michelle DuPont, Kathleen Burke, Steven W. Criscione, Laura Prickett, Jingwen Zhang, Ho Man Chan, Lisa Drew, Yi Yao
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 3271.
https://doi.org/10.1158/1538-7445.AM2022-3271
Published: 15 June 2022
View articletitled, Abstract 3271: BRD4 inhibition enhances the acalabrutinib tumor response by modulating PAX5 and interferon signaling in ABC-DLBCL
Journal Articles

Abstract 1813: The genetic makeup of patient-derived xenografts shapes the immune landscape of humanized mice tumors

Maneesh Singh, Laura Bradshaw, Laura B. Prickett, Griffin Matthew, Maryann San Martin, Noel Monks, Lisa Drew, Simon T. Barry, Corinne Reimer, Theresa Proia
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1813.
https://doi.org/10.1158/1538-7445.AM2021-1813
Published: 01 July 2021
View articletitled, Abstract 1813: The genetic makeup of patient-derived xenografts shapes the immune landscape of humanized mice tumors
Journal Articles

Abstract 2500: Transient CDK9 inhibition with AZD4573 modulates Bfl-1 in preclinical lymphoma models

Scott Boiko, Theresa Proia, Maryann San Martin, Lisa Drew, Wenlin Shao, Justin Cidado
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 2500.
https://doi.org/10.1158/1538-7445.AM2019-2500
Published: 01 July 2019
View articletitled, Abstract 2500: Transient CDK9 inhibition with AZD4573 modulates Bfl-1 in preclinical lymphoma models
Journal Articles

Abstract 1650: Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables transient target engagement for the treatment of hematologic malignancies

Bernard Barlaam, Chris De Savi, Lisa Drew, Andrew D. Ferguson, Douglas Ferguson, Chungang Gu, Janet Hawkins, Alexander W. Hird, Michelle L. Lamb, Nichole O'Connell, Kurt Pike, Theresa Proia, Maryann San Martin, Melissa M. Vasbinder, Jeff Varnes, Jianyan Wang, Wenlin Shao
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 1650.
https://doi.org/10.1158/1538-7445.AM2018-1650
Published: 01 July 2018
View articletitled, Abstract 1650: Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables transient target engagement for the treatment of hematologic malignancies
Journal Articles

Abstract 297: AZD4573: Mechanistic PKPD model linking CDK9 inhibition to Mcl1 depletion and induction of apoptosis in preclinical AML model

Douglas Ferguson, Theresa Proia, Justin Cidado, Scott Boiko, Maryann San Martin, Steven Criscione, Wenlin Shao, Lisa Drew
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 297.
https://doi.org/10.1158/1538-7445.AM2018-297
Published: 01 July 2018
View articletitled, Abstract 297: AZD4573: Mechanistic PKPD model linking CDK9 inhibition to Mcl1 depletion and induction of apoptosis in preclinical AML model
Journal Articles

Abstract 1665: AZ304, a novel dual BRAF inhibitor, exerts antitumor activity in colorectal cancers independent of BRAF status

Rui Ma, Ling Xu, Xiaofang Che, Xiujuan Qu, Lisa Drew, Minhui Shen, Tony Cheung, Yunpeng Liu
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 1665.
https://doi.org/10.1158/1538-7445.AM2018-1665
Published: 01 July 2018
View articletitled, Abstract 1665: AZ304, a novel dual BRAF inhibitor, exerts antitumor activity in colorectal cancers independent of BRAF status
Journal Articles

Abstract 310: AZD4573, a novel CDK9 inhibitor, rapidly induces cell death in hematological tumor models through depletion of Mcl1

Justin Cidado, Theresa Proia, Scott Boiko, Maryann San Martin, Steven Criscione, Douglas Ferguson, Wenlin Shao, Lisa Drew
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 310.
https://doi.org/10.1158/1538-7445.AM2018-310
Published: 01 July 2018
View articletitled, Abstract 310: AZD4573, a novel CDK9 inhibitor, rapidly induces cell death in hematological tumor models through depletion of Mcl1
Journal Articles

Abstract 306: A mechanistic rationale for combining acalabrutinib with CDK9 inhibitor, AZD4573, in ABC-DLBCL

Scott Boiko, Theresa Proia, Maryann San Martin, Justin Cidado, Wenlin Shao, Lisa Drew
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 306.
https://doi.org/10.1158/1538-7445.AM2018-306
Published: 01 July 2018
View articletitled, Abstract 306: A mechanistic rationale for combining acalabrutinib with CDK9 inhibitor, AZD4573, in ABC-DLBCL
Journal Articles

Abstract 4295: AZ’5576, a selective CDK9 inhibitor, demonstrates in vitro and in vivo activity in diverse preclinical models of non-Hodgkin lymphoma

Justin Cidado, Theresa Proia, Gareth Gregory, Izabela Todorovski, Scott Boiko, Maryann San Martin, Ricky Johnstone, Lisa Drew
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 4295.
https://doi.org/10.1158/1538-7445.AM2017-4295
Published: 01 July 2017
View articletitled, Abstract 4295: AZ’5576, a selective CDK9 inhibitor, demonstrates in vitro and in vivo activity in diverse preclinical models of non-Hodgkin lymphoma
Journal Articles

Abstract 3558: Predicting response to Mcl-1 targeting agents in NSCLC and multiple myeloma

Kristen McEachern, Greg O’Connor, Justin Cidado, Matthew Belmonte, Evan Barry, Hannah Dry, Paul Secrist, Lisa Drew
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 3558.
https://doi.org/10.1158/1538-7445.AM2016-3558
Published: 15 July 2016
View articletitled, Abstract 3558: Predicting response to Mcl-1 targeting agents in NSCLC and multiple myeloma
Journal Articles

Abstract 3572: AZ5576, a novel potent and selective CDK9 inhibitor, induces rapid cell death and achieves efficacy in multiple preclinical hematological models

Justin Cidado, Minhui Shen, Michael Grondine, Scott Boiko, Haiyun Wang, Alexandra Borodovsky, Anne Marie Mazzola, Alan Wu, Deborah Lawson, Douglas Ferguson, Beirong Gao, Andy Cui, Celina D’Cruz, Lisa Drew
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 3572.
https://doi.org/10.1158/1538-7445.AM2016-3572
Published: 15 July 2016
View articletitled, Abstract 3572: AZ5576, a novel potent and selective CDK9 inhibitor, induces rapid cell death and achieves efficacy in multiple preclinical hematological models
Journal Articles

Abstract 3362: Miniaturized PBPK model improves pharmacodynamic characterization and physiological interpretability for compounds with profound hysteresis in tumor.

Francis D. Gibbons, Dan Widzowski, Minhui Shen, Jane Cheng, Lisa Drew, Jamal C. Saeh, Douglas Ferguson
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 3362.
https://doi.org/10.1158/1538-7445.AM2013-3362
Published: 15 April 2013
View articletitled, Abstract 3362: Miniaturized PBPK model improves pharmacodynamic characterization and physiological interpretability for compounds with profound hysteresis in tumor.
Journal Articles

Abstract 2461: Design and synthesis of AZD3463, a novel orally bioavailable dual ALK and IGF1R inhibitor, inhibits growth of crizotinib resistance cell lines with multiple mechanisms of acquired resistance.

Jamal C. Saeh, Bin Yang, Tim Pontz, Kumar Thakur, Bo Peng, Lisa Drew, Caroline Rivard, Dan Widzowski, Jane Cheng, Douglas Ferguson, Brenda McDermott, Minhui Shen, John McNulty, Ryohei Katayama, Jeffrey Engleman, Alice Shaw, Daniel Russell, Graeme Smith
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 2461.
https://doi.org/10.1158/1538-7445.AM2013-2461
Published: 15 April 2013
View articletitled, Abstract 2461: Design and synthesis of AZD3463, a novel orally bioavailable dual ALK and IGF1R inhibitor, inhibits growth of crizotinib resistance cell lines with multiple mechanisms of acquired resistance.
Journal Articles

Abstract 919: AZD3463, a novel ALK/IGF1R inhibitor, overcomes multiple mechanisms of acquired resistance to crizotinib.

Lisa Drew, Jane Cheng, Jeffrey Engelman, Douglas Ferguson, Ryohei Katayama, Brenda McDermott, Jamal Saeh, Alice Shaw, Minhui Shen, Dan Widzowski, Allan Wu, Graeme Smith
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 919.
https://doi.org/10.1158/1538-7445.AM2013-919
Published: 15 April 2013
View articletitled, Abstract 919: AZD3463, a novel ALK/IGF1R inhibitor, overcomes multiple mechanisms of acquired resistance to crizotinib.